Condition
Other Cancers
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
1Total
Early P 1 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01383135Early Phase 1Completed
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
NCT03146520Completed
Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection
NCT02540850Completed
CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
Showing all 3 trials